Management of Symptomatic Advanced Pancreatic Adenocarcinoma

"The 14-EISCP starts with the end of the first visit medical for patients who have symptoms suspicious of or confirmed symptomatic aPDAC (ECOG PS ≥ 2 and/or initially ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel):~The The 14-EISCP will include:~* Pain management,~* Nutritional management,~* Pathological examination and site of biopsy,~* Imaging,~* Endoscopy for diagnosis purpose or for biliary/duodenal stenting.~After the 14-EISCP, patients will receive best supportive care or chemotherapy according to their ECOG PS status:~* ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~* ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patients will be treated by: FOLFOX7 lightened"